Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety of Enzalutamide in Progressive CRPC Post-Docetaxel
NCT02124668Phase 2Completed
- Sponsor
- Astellas Pharma
- Start
- Sep 2014
- Primary completion
- May 2017
- Modality
- Small Molecules
- Countries
- 2
01
Overview
A Phase 2 trial of enzalutamide in castration-resistant prostate cancer (CRPC), sponsored by Astellas Pharma. Started Sep 2014; status: completed.
02
Drugs
enzalutamide
03
Conditions
castration-resistant prostate cancer (CRPC)
Beyond the preview
Go deeper on NCT02124668.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02124668.